InspireMD, Inc.

InspireMD, Inc. is dedicated to advancing healthcare through the development of innovative medical devices, particularly its CGuard Prime Carotid Stent System, which addresses key challenges in carotid revascularization. Founded in 2005 in Boston, US, InspireMD, Inc. focuses on developing medical devices that enhance patient outcomes.

The company is led by CEO Marvin Slosman, who has a history of founding and managing healthcare ventures. Since its inception, InspireMD has not undergone significant pivots or changes in strategy and operates independently without known subsidiaries. InspireMD, Inc. specializes in the development of innovative medical devices, particularly focusing on its flagship product, the CGuard Prime Carotid Stent System.

This advanced carotid stent features a dual-layer design with a MicroNet™ mesh to mitigate risks associated with plaque prolapse and embolization. The CGuard Prime is indicated for patients at high risk for adverse events from carotid endarterectomy, designed for use with specific embolic protection devices, thus enhancing its efficacy and safety profile. Target clientele includes healthcare providers and hospitals across the US, Europe, and select international markets, aimed at patients requiring carotid interventions. In 2024, InspireMD reported a revenue of USD 7.

01 mn, with an EBITDA of USD -33. 22 mn. The company's revenue model centers on direct sales of its medical devices, primarily the CGuard Prime Carotid Stent System, sold to healthcare providers and hospitals through B2B relationships. This model is supported by partnerships with distributors to enhance market reach, particularly in non-U.

S. regions. InspireMD plans to expand its product line with upcoming innovations in carotid intervention technology, although specific product launch dates are not outlined. The company aims to penetrate new markets in Europe and Asia by 2025, leveraging recent funding to bolster research and development and enhance marketing strategies in these regions.

Additionally, funds will support strategic partnerships that facilitate entry into these new markets.